PHIO · NASDAQ
Phio Pharmaceuticals (PHIO) Stock Price & Fundamentals
Phio Pharmaceuticals (PHIO) closed at $244.07 on Oct 9, 2026, up 0.32% from the previous close of $243.30.
Share price, past year
1Y +13.83%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $244.07 |
| Sep 30, 2026 | $240.78 |
| Aug 31, 2026 | $236.09 |
| Jul 31, 2026 | $243.84 |
| Jun 30, 2026 | $238.38 |
| May 29, 2026 | $221.39 |
| Apr 30, 2026 | $225.06 |
| Mar 31, 2026 | $224.94 |
| Feb 27, 2026 | $214.65 |
| Jan 30, 2026 | $198.92 |
| Dec 31, 2025 | $208.18 |
| Nov 28, 2025 | $199.32 |
| Oct 31, 2025 | $203.73 |
Key statistics
- Market cap
- $2.84B
- P/E (TTM)
- —
- EPS (TTM)
- —
- Revenue (TTM)
- —
- Net income (TTM)
- −$12.90M
- Shares outstanding
- 11.6M
- Dividend yield
- —
- 52-week range
- $194.70 – $247.56
Phio Pharmaceuticals's market cap is $2.84B, based on a share price of $244.07 and 11.6M shares outstanding as of Jun 30, 2026.
Financials
Phio Pharmaceuticals reported revenue of $0.00 for fiscal 2020, down 100.00% from fiscal 2019.
Phio Pharmaceuticals reported a net loss of $8.70M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2020ended Dec 31, 2020 | $0.00 | −100.0% | −$8.79M | — | −$1.92 | −$8.82M |
| FY2019ended Dec 31, 2019 | $21.00K | −84.8% | −$8.91M | −42,419.1% | −$19.33 | −$8.72M |
| FY2018ended Dec 31, 2018 | $138.00K | +820.0% | −$7.36M | −5,333.3% | −$57.46 | −$7.53M |
| FY2017ended Dec 31, 2017 | $15.00K | −21.1% | −$12.45M | −83,013.3% | −$5.52 | −$9.72M |
| FY2016ended Dec 31, 2016 | $19.00K | −44.1% | −$8.99M | −47,336.8% | −$16.41 | — |
| FY2015ended Dec 31, 2015 | $34.00K | −91.5% | — | — | −$2.10 | — |
| FY2013ended Dec 31, 2013 | $399.00K | +311.3% | — | — | — | −$6.39M |
| FY2012ended Dec 31, 2012 | $97.00K | — | — | — | — | — |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q4 FY2020ended Dec 31, 2020 | $0.00 | — | — |
| Q3 FY2020ended Sep 30, 2020 | $0.00 | — | — |
| Q2 FY2020ended Jun 30, 2020 | $0.00 | — | — |
| Q1 FY2020ended Mar 31, 2020 | $0.00 | — | — |
| Q4 FY2019ended Dec 31, 2019 | $0.00 | — | — |
| Q3 FY2019ended Sep 30, 2019 | $0.00 | — | — |
| Q2 FY2019ended Jun 30, 2019 | $0.00 | — | — |
| Q1 FY2019ended Mar 31, 2019 | $21.00K | — | — |
Company profile
- Name
- Phio Pharmaceuticals Corp.
- Ticker
- PHIO
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 411 Swedeland Road, Suite 23-1080, King Of Prussia, PA 19406
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001533040
Recent SEC filings
- Sep 28, 2026
- Sep 14, 2026
- Aug 6, 2026
- Aug 6, 2026
- Jul 21, 2026
- May 7, 2026
- May 7, 2026
- Apr 8, 2026
Frequently asked questions
What is Phio Pharmaceuticals's stock price?
Phio Pharmaceuticals (PHIO) closed at $244.07 on Oct 9, 2026, up 0.32% from the previous close of $243.30.
What is Phio Pharmaceuticals's market cap?
Phio Pharmaceuticals's market cap is $2.84B, based on a share price of $244.07 and 11.6M shares outstanding as of Jun 30, 2026.
How much revenue does Phio Pharmaceuticals make?
Phio Pharmaceuticals reported revenue of $0.00 for fiscal 2020, down 100.00% from fiscal 2019.
Does Phio Pharmaceuticals pay a dividend?
Phio Pharmaceuticals's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Phio Pharmaceuticals Corp.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures